Attitudes of Patients with Adrenoleukodystrophy Towards Sex-Specific Newborn Screening

Overview

Journal Int J Neonatal Screen

Date 2023 Sep 27

PMID 37754777

Authors

Hemmo A F Yska

Lidewij Henneman

Rinse W Barendsen

Marc Engelen

Stephan Kemp

Affiliations

Soon will be listed here.

Abstract

Newborn screening (NBS) for X-linked adrenoleukodystrophy (ALD) can identify affected individuals before the onset of life-threatening manifestations. Some countries have decided to only screen boys (sex-specific screening). This study investigates the attitudes of individuals with ALD towards sex-specific NBS for ALD. A questionnaire was sent to all patients in the Dutch ALD cohort. Invitees were asked who they thought should be screened for ALD: only boys, both boys and girls or neither. The motives and background characteristics of respondents were compared between screening preferences. Out of 108 invitees, 66 participants (61%), 38 men and 28 women, participated in this study. The majority (n = 53, 80%) favored screening both newborn boys and girls for ALD, while 20% preferred boys only. None of the respondents felt that newborns should not be screened for ALD. There were no differences in the background characteristics of the respondents between screening preferences. Our study revealed a diverse range of motivations underlying respondents' screening preferences. This study is one of the first to investigate the attitudes of patients towards sex-specific screening for ALD. The outcomes of this study can offer insights to stakeholders engaged in the implementation of NBS programs. ALD patients are important stakeholders who can provide valuable input in this process.

Citing Articles

Psychological Impact of Presymptomatic X-Linked ALD Diagnosis and Surveillance: A Small Qualitative Study of Patient and Parent Experiences.

Videbaek C, Gronborg S, Lund A, Olesen M Int J Neonatal Screen. 2024; 10(4).

PMID: 39584996 PMC: 11587114. DOI: 10.3390/ijns10040073.

References

Fijen L, Petersen R, Levi M, Lakeman P, Henneman L, Cohn D . Patient perspectives on reproductive options for hereditary angioedema: A cross-sectional survey study. J Allergy Clin Immunol Pract. 2022; 10(9):2483-2486.e1. DOI: 10.1016/j.jaip.2022.05.030. View

Blom M, Schoenaker M, Hulst M, de Vries M, Weemaes C, Willemsen M . Dilemma of Reporting Incidental Findings in Newborn Screening Programs for SCID: Parents' Perspective on Ataxia Telangiectasia. Front Immunol. 2019; 10:2438. PMC: 6851017. DOI: 10.3389/fimmu.2019.02438. View

Albersen M, van der Beek S, Dijkstra I, Alders M, Barendsen R, Bliek J . Sex-specific newborn screening for X-linked adrenoleukodystrophy. J Inherit Metab Dis. 2022; 46(1):116-128. PMC: 10092852. DOI: 10.1002/jimd.12571. View

Blom M, Bredius R, Jansen M, Weijman G, Kemper E, Vermont C . Parents' Perspectives and Societal Acceptance of Implementation of Newborn Screening for SCID in the Netherlands. J Clin Immunol. 2020; 41(1):99-108. PMC: 7846522. DOI: 10.1007/s10875-020-00886-4. View

McHugh M . The chi-square test of independence. Biochem Med (Zagreb). 2013; 23(2):143-9. PMC: 3900058. DOI: 10.11613/bm.2013.018. View

Kemp S, Pujol A, Waterham H, van Geel B, Boehm C, Raymond G . ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat. 2001; 18(6):499-515. DOI: 10.1002/humu.1227. View

Barendsen R, Dijkstra I, Visser W, Alders M, Bliek J, Boelen A . Adrenoleukodystrophy Newborn Screening in the Netherlands (SCAN Study): The X-Factor. Front Cell Dev Biol. 2020; 8:499. PMC: 7311642. DOI: 10.3389/fcell.2020.00499. View

Kemper A, Brosco J, Marie Comeau A, Green N, Grosse S, Jones E . Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet Med. 2016; 19(1):121-126. PMC: 5182180. DOI: 10.1038/gim.2016.68. View

Petros M . Revisiting the Wilson-Jungner criteria: how can supplemental criteria guide public health in the era of genetic screening?. Genet Med. 2012; 14(1):129-34. DOI: 10.1038/gim.0b013e31823331d0. View

10.

Huffnagel I, Dijkgraaf M, Janssens G, van Weeghel M, van Geel B, Poll-The B . Disease progression in women with X-linked adrenoleukodystrophy is slow. Orphanet J Rare Dis. 2019; 14(1):30. PMC: 6367840. DOI: 10.1186/s13023-019-1008-6. View

11.

Costakos D, Abramson R, Edwards J, Rizzo W, Best R . Attitudes toward presymptomatic testing and prenatal diagnosis for adrenoleukodystrophy among affected families. Am J Med Genet. 1991; 41(3):295-300. DOI: 10.1002/ajmg.1320410307. View

12.

Engelen M, Kemp S, de Visser M, van Geel B, Wanders R, Aubourg P . X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012; 7:51. PMC: 3503704. DOI: 10.1186/1750-1172-7-51. View

13.

Dubey P, Raymond G, Moser A, Kharkar S, Bezman L, Moser H . Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr. 2005; 146(4):528-32. DOI: 10.1016/j.jpeds.2004.10.067. View

14.

Lee S, Clinard K, Young S, Rehder C, Fan Z, Calikoglu A . Evaluation of X-Linked Adrenoleukodystrophy Newborn Screening in North Carolina. JAMA Netw Open. 2020; 3(1):e1920356. PMC: 7042889. DOI: 10.1001/jamanetworkopen.2019.20356. View

15.

Broadbent E, Wilkes C, Koschwanez H, Weinman J, Norton S, Petrie K . A systematic review and meta-analysis of the Brief Illness Perception Questionnaire. Psychol Health. 2015; 30(11):1361-85. DOI: 10.1080/08870446.2015.1070851. View

16.

Huang H, Chu K, Chien Y, Wei M, Wu S, Wang S . Tandem mass neonatal screening in Taiwan--report from one center. J Formos Med Assoc. 2006; 105(11):882-6. DOI: 10.1016/S0929-6646(09)60173-X. View

17.

van der Pal S, Wins S, Klapwijk J, van Dijk T, Kater-Kuipers A, van der Ploeg C . Parents' views on accepting, declining, and expanding newborn bloodspot screening. PLoS One. 2022; 17(8):e0272585. PMC: 9387838. DOI: 10.1371/journal.pone.0272585. View

18.

Turk B, Theda C, Fatemi A, Moser A . X-linked adrenoleukodystrophy: Pathology, pathophysiology, diagnostic testing, newborn screening and therapies. Int J Dev Neurosci. 2020; 80(1):52-72. PMC: 7041623. DOI: 10.1002/jdn.10003. View

19.

Shimozawa N, Takashima S, Kawai H, Kubota K, Sasai H, Orii K . Advanced Diagnostic System and Introduction of Newborn Screening of Adrenoleukodystrophy and Peroxisomal Disorders in Japan. Int J Neonatal Screen. 2021; 7(3). PMC: 8395936. DOI: 10.3390/ijns7030058. View

20.

Cornel M, Rigter T, Jansen M, Henneman L . Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide. J Community Genet. 2020; 12(2):257-265. PMC: 8141077. DOI: 10.1007/s12687-020-00488-y. View